Study S002071

Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain Insulin Sensitivity in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03881995
Acronym: Lixibrain01
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: TERMINATED
Enrollment: 1
Start: 2019-03-18
Primary completion: 2020-06-29
Lead sponsor: University Hospital Tuebingen
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:IGlarLixi; DRUG:Insulin Glargine 100 UNT/ML
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2018-003557-21; NIH:2018

Registered primary outcomes

Brain insulin sensitivity [Change from baseline brain insulin sensitivity at 12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.